臻鐳科技(688270.SH):2023年公司將繼續積極拓展微系統及模組客户
格隆匯5月30日丨有投資者向臻鐳科技(688270.SH)提問:2023年1季度公司營業收入同比增長33%多,約增加1000萬元,全部來自兩子公司(航芯源 、城芯科技等 ),而母公司收入同比下降70萬元,請問2023年母公司業務是否會延續2022年的不利情況,或是在哪些方面會出現轉機?
臻鐳科技回覆:尊敬的投資者,您好,母公司業務以終端射頻前端芯片、微系統及模組為主,2022年是公司微系統及模組產品落地的關鍵一年,公司微系統事業部已服務客户近十幾家,2023年公司將繼續積極拓展微系統及模組客户。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.